LAMELLASOME IPF NA
Alternative Names: LAMELLASOME IPF-NALatest Information Update: 28 Feb 2023
At a glance
- Originator Lamellar Biomedical
- Class Antifibrotics; Exosome therapies; MicroRNAs
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Idiopathic pulmonary fibrosis
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in United Kingdom (Parenteral)
- 13 Mar 2019 Lamellar Biomedical partners with Edinburgh Complex Fluid Partnership and University of Strathclyde to optimise LAMELLASOME™ technology for Idiopathic pulmonary fibrosis
- 11 Jan 2019 Preclinical trials in Idiopathic pulmonary fibrosis in United Kingdom (Parenteral)